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PainHypophosphatasia (HPP) is a rare, inherited metabolic bone disease resulting from mutations in the gene
encoding tissue non-speciﬁc alkaline phosphatase. The biochemical hallmark and key diagnostic indicator is
low alkaline phosphatase activity, which leads to a variety of clinicalmanifestations across all ages. The diagnosis
is easilymissed in adults, who frequently present with nonspeciﬁc clinical manifestations such as fractures, oste-
omalacia, and pain. Here, the pathway to diagnosis and disease course is described in an adult patient presenting
with pain. Low serumalkaline phosphatase activitywent unnoticed for 2 years until osteomalaciawas suspected,
during which time he experienced multiple fractures and progressing pain. Currently, accumulated morbidity
has rendered the patient unable to work, and treatment is focused on pain management. This case highlights
the importance of low alkaline phosphatase in the differential diagnosis of patients with musculoskeletal pain.
© 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypophosphatasia (HPP) is a rare, inherited metabolic bone disease
characterized by poor bonemineralization, leading to HPP-related rick-
ets in children and osteomalacia in adults (Rockman-Greenberg, 2013;
Whyte, 2013). HPP is caused by loss-of-function mutation(s) in the
gene (ALPL) that encodes the tissue-nonspeciﬁc isoenzyme of alka-
line phosphatase (TNSALP). Approximately 300 pathogenic muta-
tions in the ALPL gene have been identiﬁed to date (Mornet, 2015).
Inheritance may be either autosomal recessive or autosomal domi-
nant (Rockman-Greenberg, 2013; Mornet, 2015). Reduced TNSALP
activity leads to accumulation of its substrates, pyridoxal-5′-phosphate
(PLP), phosphoethanolamine (PEA), and inorganic pyrophosphate
(PPi). The excess of PPi, a potent inhibitor of bone mineralization,
leads to the mineralization defects in bone and teeth characteristic of
HPP (Whyte, 2013).
Adult-onset HPP typically manifests during middle age, although
some adults recall earlier signs of HPP such as early tooth loss or child-
hood rickets (Whyte, 2013). Regardless of age at onset of HPP, adults
may present with osteopenia, osteomalacia, recurring and/or poorly
healing fractures, pseudofractures, bone pain, joint pain caused by
chrondrocalcinosis or calciﬁc periarthritis (Whyte, 2013; Coe et al.,
1986), and/or proximal muscle weakness (Whyte, 2013; Coe et al.,
1986; Berkseth et al., 2013). As many of these symptoms are consistentethanolamine; PLP, pyridoxal-
ue-nonspeciﬁc isoenzyme of al-
This is an open access article under twith diagnosis of other diseases such as osteoporosis, osteoarthritis, and
ﬁbromyalgia, the diagnosis of HPP in adults can be challenging and eas-
ily missed (Mornet et al., 2014). Although recombinant TNSALP ap-
proved for treatment of HPP (asfotase alfa, Alexion Pharmaceuticals,
Inc.) currently exists only in Japan, Canada, and the European Union,
correct diagnosis of HPP is important as treatments for other disorders
may have adverse effects for patients with HPP; for example, treatment
with bisphosphonates (structural analogs of PPi) for a presumed diag-
nosis of osteoporosis in adults may increase fracture risk in patients
with HPP (Sutton et al., 2012).
Herein, I describe the pathway to diagnosis, unique features, and the
course and current management of a case of adult-onset HPP.
2. Case report
The patient was a 53 year-old, 6 ft tall, 215 lb Caucasian man who
was referred to rheumatology in September 2011 for intractablemuscle
and joint pain. He reported severe diffuse pain at his ﬁrst rheumatology
visit. He had no personal or known family history of metabolic bone
disease or dental disease. In August 2011, his primary care physician
diagnosed ﬁbromyalgia, based on chronic pain.
The patient ﬁrst presented in 2009 (Fig. 1) with unexplained back
and leg pain. Prior history included hypertension, hypercholesterol-
emia, and occasional insomnia, but was otherwise unremarkable. In
July 2010, he experienced unexplained bilateral swelling of his ankles.
In August 2010, he experienced non-traumatic thoracic pain; the ﬁrst
imaging in the patient's chart was a triple phase bone scan that revealed
costochondritis and a possible broken rib. A follow-upMRI of the area in
November 2010 did not identify a fracture. Pain medications, includinghe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Timeline illustrating the patient's journey to correct diagnosis of adult-onset HPP.
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was referred to a painmanagement specialist. By the time of his referral
to rheumatology in September 2011, the patient had received varying
diagnoses, including costochondritis, thoracic neuritis, chronic pain,
plantar fasciitis, compression arthralgia, and ﬁbromyalgia.
Rheumatology workup, which included a complete serology panel
with muscle enzymes, an autoimmune panel, and a full inﬂammatory
marker panel, returned no abnormal ﬁndings. Despite normal levels of
liver enzymes and creatine phosphokinase, statin-induced myopathy
was considered because his simvastatin dose had recently been in-
creased to 80 mg/day. Simvastatin was discontinued, and corticoste-
roids and muscle relaxants prescribed. The patient reported a self-
estimated 60–70% improvement in symptoms shortly thereafter, but
presented again in October 2011 with worsening pain, especially in
his ankles. Radiographs of the ankles revealed possible small fractures,
prompting an MRI in December 2011, which conﬁrmed bilateral
fractures of the medial malleoli and a non-displaced fracture in the
left ankle with a torn tendon and joint effusion. The atypical non-
traumatic nature of these fractures prompted a workup for osteomala-
cia in February 2012. Possible diagnoses included HPP,Wilson's disease,
and celiac disease. Serum magnesium, phosphorus, copper, zinc, para-
thyroid hormone, calcium, and celiac markers were within normal
limits. Alkaline phosphatase was low on multiple determinations at
27–32 IU/L (normal range: 40–115 IU/L). Upon chart review, serum
alkaline phosphatase activity was consistently low, with values below
the normal range in December 2011, April 2011, September 2010, and
June 2010 (earliest available). Pyridoxal 5′-phosphate (vitamin B6)
was 54 μg/L (normal range: 5–50 μg/L). Vitamin D was insufﬁcient
(14 ng/ml, normal range: 30–100 ng/ml) and was normalized with
supplementation. A diagnosis of HPP was indicated based on laboratory
and clinical evidence. The patient was then referred to the University of
California, Los Angeles, for genetic testing, which revealed a heterozy-
gous mutation (c.500CNT) on exon 6 of the ALPL gene (Connective
Tissue Gene Tests, Allentown, PA, USA), thereby supporting the diagno-
sis of HPP.
The patient is seen every 3months tomonitor his condition. Awhole
body bone scan in June 2012 identiﬁed increased uptake in the ankles
consistent with fracture sites but no other ﬁndings unusual for the
patient's age. In August 2013, he underwent orthopedic surgery to
have two screws placed to stabilize the ankle fractures. He has declined
both placement of stabilizer rods and experimental teriparatidetreatment. Orthopedists have expressed discomfort with further surgi-
cal treatment given the fragility of his bones. As of March 2015, the pa-
tient had progressing pain and rib fractures. He fatigues easily and
prefers appointments before noon. He regularly wraps his legs for sup-
port, and uses a cane orwalker to assist ambulation. Decreasedmobility
has rendered the patient unable towork. Pain is poorly controlledwith a
100 μg fentanyl patch/72 h and 20mg short-acting oxycodone every 4 h.
Vitamin D supplementation is provided as needed to maintain serum
concentrations within normal ranges. The patient's serum concentra-
tion of vitamin D was 48 ng/ml in April 2012 with supplementation,
after being 14 ng/ml inMarch 2012 (normal range: 30–100 ng/ml). Cur-
rent treatment is focused on painmanagement due to limited treatment
options.
3. Discussion
HPP may present with nonspeciﬁc musculoskeletal manifestations,
particularly in adults (Berkseth et al., 2013). The patient described
here initially presented with pain, and sought help from a variety of
medical specialists, including painmanagement, endocrinology, and or-
thopedic surgery, before referral to rheumatology. During his 2-year
search for the cause of his symptoms, the patient experienced progres-
sive diffuse pain and multiple fractures, which ultimately prompted a
workup for osteomalacia and the ﬁnding of low serum alkaline phos-
phatase activity. This case illustrates the difﬁculty adult patients with
HPP may have in obtaining an accurate diagnosis (Girschick et al.,
2007;Whyte et al., 2013; Sorensen and Flodgaard, 1975), and highlights
the importance of determining and recognizing the clinical signiﬁcance
of low alkaline phosphatase activity level as part of differential diagnosis
in patients with musculoskeletal complaints, including undeﬁned pain.
The clinical signiﬁcance of low serum alkaline phosphatase is under-
appreciated and may be overlooked (McKiernan et al., 2014). In the
present case, the ﬁnding of low serum alkaline phosphatase activity,
which should prompt consideration of HPP, was repeatedly missed. It
was not until osteomalacia was suspected, due to the non-traumatic
ankle fractures, that consistently low values of serum alkaline phospha-
tase were noted in the patient's record, dating back to June 2010
(earliest available, after the initial complaint of leg and back pain). As al-
kaline phosphatase levels can increase during fracture healing, thisﬁnd-
ing raised suspicion for HPP and led to examination of PLP levels, a
referral for genetic testing, and, ultimately, the correct diagnosis of HPP.
3N.A. Braunstein / Bone Reports 4 (2016) 1–4Pain is a frequent complaint by patients with HPP (Whyte, 2013;
Berkseth et al., 2013), and may result from ectopic calciﬁcation in the
joints (Berkseth et al., 2013; Guañabens et al., 2014; Metab et al.,
2012), inﬂammation (Beck et al., 2009; Girschick et al., 1999), fractures,
and/or pseudofractures (Whyte, 2013; Harper, 1989; Fallon et al., 1984;
Whyte et al., 1982). In the present case, there was no indication of
ectopic calciﬁcation by X-ray or MRI, and neither initial nor continued
complaints of generalized severe musculoskeletal pain could be
completely attributed to his fractures. Although nonsteroidal anti-
inﬂammatory drugs have been reported to improve pain in some HPP
patients (Girschick et al., 1999), they did not provide relief in this
patient. Treatment remains focused primarily on pain management
with narcotics.
HPPmay result fromautosomal recessive or autosomal dominant in-
heritance. The location of the gene mutation inﬂuences the level of re-
sidual enzymatic activity of the resulting TNSALP protein (Mornet,
2013). In the present case, a single c.500CNT mutation was found on
exon 6 of ALPL. This mutation has been determined to result in no resid-
ual alkaline phosphatase activity in an in vitro site-directedmutagenesis
assay, and it has been identiﬁed previously in a single patient with
infantile HPP, as part of a compound heterozygous genotype with a
c.571GNA mutation (Mornet, 2015). The c.571GNA mutation has been
documented in several patients, and to date, appears only to result in
symptomatic HPP when part of a compound heterozygote genotype
(Henthorn et al., 1992). Thus, the present patient may express autoso-
mal dominant inheritance, consistent with other reports of patients
with single mutations and adult onset of HPP symptoms (Whyte,
2012; Fauvert et al., 2009). Although the patient reported no family his-
tory of HPP or skeletal or dental disease, it would be of interest to screen
close family members for the mutation and possible symptoms. The
patient's chart did not state whether he had siblings or children,
which would only have been noted if they had relevant history.
Upon questioning, patients presenting with HPP in adulthood may
recall symptoms of HPP in childhood, such as early tooth loss or rickets
(Whyte, 2013). In a retrospective study at the Mayo Clinic, 9% of
patients diagnosed with HPP as adults recalled earlier symptoms
(Berkseth et al., 2013). Despite the presence of a previously reported
inactivating mutation (Mornet, 2015), the current patient did not re-
call any prior symptoms, and he is of normal stature with no peri-
odontal disease. The cause of the sudden onset of his pain and
fractures in his 50s is unclear. Epigenetic regulation and dietarymineral
intake may inﬂuence alkaline phosphatase activity (Whyte, 2013;
Mornet, 2013), while bisphosphonate treatmentmay have precipitated
symptoms in other patients with adult-onset HPP (Sutton et al., 2012;
Cundy et al., 2015). However, the majority of patients with adult-
onset HPP also lack a clear precipitating cause, and the factors contrib-
uting to a shift from a patient being an asymptomatic carrier to
exhibiting active disease require further investigation.
The course of HPP is highly variable and not well characterized in
adults. In the present case, a rapid accumulation ofmorbidities followed
the initial onset of symptoms in 2009, leading to progressive disability,
which ultimately rendered the patient unable to work. This progression
is remarkable but not unique (Weinstein and Whyte, 1981a, 1981b;
Anderton, 1979; Schalin-Jäntti et al., 2010), although several of the
cases with similar adult trajectories report onset of symptoms prior to
adulthood. Together, these cases illustrate the potential severity of
HPP with risk of deterioration and decreased quality of life in adult
patients with HPP regardless of age at onset, and the need for careful
monitoring and management of patients with HPP.
Asfotase alfa, a recombinant human TNSALP enzyme-replacement
therapy, is undergoing development as a medical treatment for HPP
(Whyte et al., 2012), and was recently approved by the Japanese,
Canadian, and European Union health authorities. Current treatment is
typically focused on symptom management, including medications for
pain and surgical ﬁxation to aid fracture healing (Coe et al., 1986), as de-
scribed for this patient. Attempted treatment of HPPwith teriparatide, abone anabolic agent (Hodsman et al., 2005), has resulted in some
patients reporting improvement in pain and fracture healing over
1–3 years of follow-up (Doshi et al., 2009; Silva et al., 2012; Camacho
et al., 2008;Whyte et al., 2007),while others experienced only transient
beneﬁts (Schalin-Jäntti et al., 2010; Camacho et al., 2008; Gagnon et al.,
2010) or are unable to tolerate the treatment due to increased pain
(Laroche, 2012). These reports show, atmost, minimal and transient ef-
fects of teriparatide on alkaline phosphatase and substrate levels, which
do not attain normal ranges evenwhen some clinical beneﬁt is observed
(Schalin-Jäntti et al., 2010; Doshi et al., 2009; Camacho et al., 2008;
Whyte et al., 2007; Gagnon et al., 2010). Effects of teriparatide may de-
pend on the level of residual alkaline phosphatase activity associated
with a given genotype (Whyte, 2013). The patient described herein de-
clined teriparatide treatment based on his independent assessment of
the beneﬁt:risk of teriparatide treatment for HPP. In managing patients
withHPP, it is critical to avoid use of bisphosphonates due to their struc-
tural similarity with PPi (Drake et al., 2008). As elevation of PPi is the
primary mechanism underlying mineralization deﬁcits seen in HPP,
bisphosphonates further impair bone mineralization in patients with
HPP (Sutton et al., 2012), and result in exacerbation of disease (Cundy
et al., 2015). Caution is also needed when considering supplemental vi-
tamin D, as vitamin D supplementation in patients with HPPmay result
in hypercalcemia (Berkseth et al., 2013; Eisenberg and Pimstone, 1967).
The patient presented herein represents one example of the broad
spectrum of presentations associated with HPP, including pain, recur-
rent, non-traumatic, and non-healing fractures, progressive loss of mo-
bility, and diminished quality of life. This case illustrates the challenges
of recognizing, diagnosing, and treating HPP, and highlights the need to
consider serum alkaline phosphatase activity levels in patients present-
ing with nonspeciﬁc pain.
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